Physician profile
Thomas Wheeler
NPI 1154536506
$8,628.48
in general payments reported to CMS, 2019-2025
42 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $2,055 · 2021: $798 · 2022: $1,133 · 2023: $1,134 · 2024: $1,478 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,974 · Education: $33.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,973.87 |
| Education | $33.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $2,418.28 | 2019-2024 | Renal - Acute, Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $653.88 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Calliditas Therapeutics US INC. | $542.63 | 2023-2025 | Tarpeyo |
| Amgen INC. | $404.13 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $394.02 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $374.34 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $335.78 | 2021-2025 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $306.69 | 2019-2024 | Ultomiris |
| Novo Nordisk INC | $288.96 | 2023-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $270.58 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $257.62 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $231.74 | 2024-2025 | |
| Glaxosmithkline, LLC. | $215.51 | 2021-2024 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $199.91 | 2019-2024 | Veltassa |
| Intuitive Surgical, INC. | $178.57 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.